Maximizing the cost-effectiveness of lipid-lowering therapy

Archives of Internal Medicine

Volumn 158, Issue 18, 1998, Pages 1977-1989

  Jacobson, Terry A ^a,e,f,g   Schein, Jeffrey R ^b   Williamson, Amy ^c,h   Ballantyne, Christie M ^d,e,f,g,i  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Lewin TAG Inc   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e BRISTOL MYERS SQUIBB   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

^g PFIZER INC   (United States)

^h Novartis Pharmaceuticals Corporation

ⁱ Novartis and Merck

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ATHEROSCLEROSIS; CAUSE OF DEATH; CHOLESTEROL METABOLISM; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG COST; ENZYME INHIBITION; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; MEDICAID; MEDICARE; MORTALITY; PATIENT COMPLIANCE; PRIMARY PREVENTION; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; STROKE; TREATMENT INDICATION; TREATMENT PLANNING;

ANTICHOLESTEREMIC AGENTS; CAROTID STENOSIS; CEREBROVASCULAR DISORDERS; CLINICAL TRIALS; CORONARY DISEASE; COST-BENEFIT ANALYSIS; FATTY ACIDS, MONOUNSATURATED; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; LOVASTATIN; PRAVASTATIN; PYRROLES; SIMVASTATIN;

EID: 0032511746     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.158.18.1977     Document Type: Review

References (101)

1. American Heart Association. 1998 Heart and Stroke Statistical Update. Dallas, Tex: American Heart Association; 1997.
2. Centers for Disease Control and Prevention. Medical care spending: United States. MMWR Morb Mortal Wkly Rep. 1994;43:581-586.
3. Hodgson T, Kopstein A. Health care expenditures for major diseases in 1980. Health Care Financing Rev. 1984;5:1-12.
4. Sempos CT, Cleeman JI, Carroll MD, et al. Prevalence of high blood cholesterol among US adults: an update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel. JAMA. 1993;269: 3009-3014.
5. Winslow R. Powerful medications for cholesterol pose a paradox for HMOs. Wall Street Journal. December 6, 1996:A1, A11.
6. Wittels EH, Hay JW, Gotto AM Jr. Medical costs of coronary artery disease in the United States. Am J Cardiol. 1990;65:432-440.
7. Dobkin B. The economic impact of stroke. Neurology. 1995;45(suppl 1):S6-S9.
8. Holloway RG, Witter DM Jr, Lawton KB, Lipscomb J, Samsa G. Inpatient costs of specific cerebrovascular events at five academic medical centers. Neurology. 1996;46:854-860.
9. Taylor TN, Davis PH, Torner JC, Holmes J, Meyer JW, Jacobson MF. Lifetime cost of stroke in the United States. Stroke. 1996;27:1459-1466.
10. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: a new look at old data. Circulation. 1995;91:2274-2282.
11. Peters TK, Muratti EN, Mehra M. Efficacy and safety of fluvastatin in women with primary hypercholesterolemia. Drugs. 1994;47(suppl 2):64-72.
12. Steinhagen-Thiessen E, for the Simvastatin Pravastatin European Study Group. Comparative efficacy and tolerability of 5 and 10 mg simvastatin and 10 mg pravastatin in moderate primary hypercholesterolemia. Cardiology. 1994;85:244-254.
13. Lovastatin Pravastatin Study Group. A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia. Am J Cardiol. 1993;71:810-815.
14. Sacks FM, Pfeffer MA, Moye LA, et al, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996; 335:1001-1009.
15. Shepherd J, Cobbe SM, Ford I, et al, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
16. Jukema JW, Bruschke AVG, van Boven AJ, et al, for the REGRESS Study Group. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995;91:2528-2540.
17. Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) Study results, I: efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med. 1991;151:43-49.
18. Farmer JA, Washington LC, Jones PH, Shapiro DR, Gotto AM Jr, Mantel G, for the Simvastatin and Lovastatin Multicenter Study Participants. Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia. Clin Ther. 1992;14:708-717.
19. Douste-Blazy P, Ribeiro VG, Seed M, and the European Study Group. Comparative study of the efficacy and tolerability of simvastatin and pravastatin in patients with primary hypercholesterolemia. Drug Invest. 1993;6:353-361.
20. Lambrecht LJ, Malini PL, for the European Study Group. Efficacy and tolerability of simvastatin 20 mg vs pravastatin 20 mg in patients with primary hypercholesterolemia. Acta Cardiol. 1993; 48:541-554.
21. Zocor (simvastatin) [package insert]. West Point, Pa: Merck & Co; 1996.
22. Jones P, Kafonek S, Laurora I, Hunninghake D, for the CURVES Investigators. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998;81:582-587.
23. Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA. 1996;275:128-133.
24. Davidson MH, Stein EA, Dujovne CA, et al. The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol. 1997;79:38-42.
25. Blankenhom DH, Azen SP, Kramsch DM, etal. Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med. 1993;119:969-976.
26. Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial. Circulation. 1994;89:959-968.
27. Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med. 1997;336:153-162.
28. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
29. MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet. 1994;344:633-638.
30. Pitt B, Mancini GBJ, Ellis SG, Rosman HS, Park J-S, McGovern ME, for the PLAC I Investigators. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC I): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol. 1995;26:1133-1139.
31. Sacks FM, Pasternak RC, Gibson CM, Rosner B, Stone PH, for the Harvard Atherosclerosis Reversibility Project (HARP) Group. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Lancet. 1994;344:1182-1186.
32. Herd JA, Ballantyne CM, Farmer JA, et al, for the LCAS Investigators. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol. 1997;80:278-286.
33. Furberg CD, Adams HP Jr, Applegate WB, et al, for the Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation. 1994;90:1679-1687.
34. Hodis HN, Mack WJ, LaBree L, et al. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: a randomized controlled clinical trial. Ann Intern Med. 1996;124: 548-556.
35. Salonen R, Nyyssönen K, Porkkala E, et al. Kuopio Atherosclerosis Prevention Study (KAPS): a population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation. 1995;92:1758-1764.
36. Crouse JR III, Byington RP, Bond MG, et al. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Am J Cardiol. 1995; 75:455-459.
37. Downs JR, Clearfield M, Weis S, et al, for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-1622.
38. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
39. Tonkin A. Long-term Intervention With Pravastatin in Ischaemic Disease (LIPID). Presented at: the American Heart Association Scientific Sessions; November 12, 1997; Orlando, Fla.
40. National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation. 1994;89:1329-1445.
41. Yusuf S, Anand S. Cost of prevention: the case of lipid lowering. Circulation. 1996;93:1774-1776.
42. Neaton JD, Wentworth D, for the Multiple Risk Factor Intervention Trial Research Group. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease: overall findings and differences by age for 316 099 white men. Arch Intern Med. 1992;152:56-64.
43. Sacks FM, Moyé LA, Davis BR, et al. Relationship between plasma LDL concentrations during drug treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation. 1998;97: 1446-1452.
44. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 1998;97:1440-1445.
45. Pedersen TR, Olsson AG, Færgeman O, et al, for the Scandinavian Simvastatin Survival Study Group. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation. 1998;97:1453-1460.
46. Grundy SM. Statin trials and goals of cholesterol-lowering therapy. Circulation. 1998;97:1436-1439.
47. Crouse JR III, Byington RP, Hoen HM, Furberg CD. Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med. 1997;157:1305-1310.
48. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials. JAMA. 1997;278:313-321.
49. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC, for the Panel on Cost-Effectiveness in Health and Medicine. The role of cost-effectiveness analysis in health and medicine. JAMA. 1996;276:1172-1177.
50. Freund D, Dittus R. Principles of pharmacoeconomic analysis of drug therapy. Pharmacoeconomics. 1992;1:20-32.
51. Goldman L, Garber AM, Grover SA, Hlatky MA. Task Force 6: cost effectiveness of assessment and management of risk factors. J Am Coll Cardiol. 1996;27:1020-1030.
52. Tengs TO, Adams ME, Pliskin JS, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal. 1995;15:369-390.
53. Goldman L, Weinstein MC, Goldman PA, Williams LW. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA. 1991; 265:1145-1151.
54. Ashraf T, Hay JW, Pitt B, et al. Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease. Am J Cardiol. 1996;78:409-414.
55. Pedersen TR, Kjekshus J, Berg K, et al, for the Scandinavian Simvastatin Survival Study Group. Cholesterol lowering and the use of healthcare resources: results of the Scandinavian Simvastatin Survival Study. Circulation. 1996;93:1796-1802.
56. Johannesson M, Jönsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H, for the Scandinavian Simvastatin Survival Study Group. Cost effectiveness of Simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med. 1997;336: 332-336.
57. Hamilton VH, Racicot F-E, Zowall H, Coupal L, Grover SA. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease: estimating the benefits of increasing HDL-C. JAMA. 1995;273:1032-1038.
58. Hay JW, Wittels EH, Gotto AM Jr. An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction. Am J Cardiol. 1991;67:789-796.
59. Martens LL, Guibert R. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease. Clin Ther. 1995;16:1052-1062.
60. Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D, for the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J. 1994;15:1300-1331.
61. Ramsay LE, Haq IU, Jackson PR, Yeo WW, Pickin DM, Payne JN. Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table. Lancet. 1996; 348:387-388.
62. Haq IU, Ramsay LE, Pickin DM, Yeo WW, Jackson PR, Payne JN. Lipid-lowering tor prevention of coronary heart disease: what policy now? Clin Sci (Colch). 1996;91:399-413.
63. Kinosian B, Glick H, Garland G. Cholesterol and coronary heart disease: predicting risks by levels and ratios. Ann Intern Med. 1994;121:641-647.
64. Grover SA, Palmer CS, Coupall L. Serum lipid screening to identify high risk individuals for coronary death: the results of the Lipid Research Clinics prevalence cohort. Arch Intern Med. 1994; 154:679-684.
65. Anderson KM, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk profile: a statement for health professionals. Circulation. 1991;83:356-362.
66. Kannel WB, D'Agostino RB, Anderson KM, et al. Coronary Risk and Stroke Prediction Chart and Worksheet. Dallas, Tex: American Heart Association; 1993.
67. Anderson KM, Odell PM, Wilson PWF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1991;121:293-298.
68. Laurier D, Nguyen PC, Cazelles B, Segond P, and the PCV-METRA Group. Estimation of CHD risk in a French working population using a modified Framingham model. J Clin Epidemiol. 1994;47:1353-1364.
69. Frohlich J, Fodor G, McPherson R, Genest J, Langner N, for the Dyslipidemia Working Group of Health Canada. Rationale for and outline of the recommendations of the Working Group on Hypercholesterolemia and Other Dyslipidemias: interim report. Can J Cardiol. 1998;14(supplA):17A-21A.
70. West of Scotland Coronary Prevention Group. West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet. 1996;348:1339-1342.
71. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. Lancet. 1985;291:97-104.
72. Heller RF, Chinn S, Pedoe HD, Rose G. How well can we predict coronary heart disease? findings in the United Kingdom Heart Disease Prevention Project. BMJ. 1984;288:1409-1411.
73. Ridker PM. Association of hemostatic and thrombotic factors with cardiovascular risk. In: Schafer AI, ed. Molecular Mechanisms of Hypercoagulable States. Austin, Tex: Landes Bioscience; 1997.
74. Schaefer EJ, Lamon-Fava S, Jenner JL, et al. Lipoprotein(a) levels and risk of coronary heart disease in men: the Lipid Research Clinics Coronary Primary Prevention Trial. JAMA. 1994;271:999-1003.
75. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA. 1993;270:2195-2199.
76. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease: the Framingham Study. JAMA. 1987;258:1183-1186.
77. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW, for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 1995;332:635-641.
78. de Maat MP, Pietersma A, Kofflard M, Sluiter W, Kluft C. Association of plasma fibrinogen levels with coronary artery disease, smoking and inflammatory markers. Atherosclerosis. 1996;121:185-191.
79. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA. 1995;274:1049-1057.
80. Rallidis LS, Megalou AA, Papageorgakis NH, Trikas AG, Chatzidimitriou GI, Tsitouris GK. Plasminogen activator inhibitor 1 is elevated in the children of men with premature myocardial infarction. Thromb Haemost. 1996;76:417-421.
81. Ridker PM, Cushman M, Stampfer M, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
82. Kuller L, Borhani N, Furberg C, et al. Prevalence of subclinical atherosclerosis and cardiovascular disease and association with risk factors in the Cardiovascular Health Study. Am J Epidemiol. 1994;139:1164-1179.
83. Arad Y, Spadaro LA, Goodman K, et al. Predictive value of electron beam computed tomography of the coronary arteries: 19-month follow-up of 1173 asymptomatic subjects. Circulation. 1996;93:1951-1953.
84. Wexler L, Brundage B, Crouse J, et al. Coronary artery calcification: pathophysiology, epidemiology, imaging methods, and clinical implications: a statement for health professionals from the American Heart Association. Circulation. 1996;94:1175-1192.
85. Brundage BH. Beyond perfusion with ultrafast computed tomography. Am J Cardiol. 1995;75: 69D-73D.
86. Fusman B, Wolfkiel CJ. Ultrafast computed tomography for detection of coronary artery calcification. Am J Card Imaging. 1995;9:206-212.
87. Shepherd J, for the WOSCOPS Group. The West of Scotland Coronary Prevention Study (WOSCOPS): benefits of pravastatin therapy in compliant subjects [abstract]. Circulation. 1996; 94:I-539.
88. McDermott MM, Schmitt B, Wallner E. Impact of medication nonadherence on coronary heart disease outcomes. Arch Intern Med. 1997;157: 1921-1929.
89. Insull W. The problem of compliance to cholesterol altering therapy. J Intern Med. 1997;241: 317-325.
90. Houston-Miller N, Hill M, Kottke T, Ockene IS. The multilevel compliance challenge: recommendations for a call to action: a statement for healthcare professionals. Circulation. 1997;95: 1085-1090.
91. O'Brien T, Nguyen TT. Lipids and lipoproteins in women. Mayo Clin Proc. 1997;72:235-244.
92. Bush TL. Evidence for primary and secondary prevention of coronary artery disease in women taking oestrogen replacement therapy. Eur Heart J. 1996;17(suppl D):9-14.
93. Jacobson TA. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor therapy in the managed care era. Am J Cardiol. 1996;78(suppl 6A);32-41.
94. Sacks FM, Moye LA, Davis BR, et al. The influence on coronary events of lipid therapy during treatment with pravastatin: the CARE trial [abstract]. Circulation. 1997;96:I-66.
95. Packard CJ. Relationship between LDL-C changes and CHD event reduction with pravastatin in the West of Scotland Coronary Prevention Study (WOSCOPS) [abstract]. Circulation. 1997;96:I-107.
96. Drug Topics Red Book Update. Montvale, NJ: Medical Economics: July 1998.
97. Jacobson TA. Preventing CHD in the managed care era: improving the cost-effectiveness of lipid lowering therapy. Am J Managed Care. 1997;3 (suppl):S29-S41.
98. Oster G, Borok GM, Menzin J, et al. Cholesterol-Reduction Intervention Study (CRIS): a randomized trial to assess effectiveness and costs in clinical practice. Arch Intern Med. 1996;156:731-739.
99. Schrott HG, Stein EA, Dujovne CA, et al. Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy. Am J Cardiol. 1995;75:34-39.
100. Pearson TA, McBride PE, Miller NH, Smith SC Jr. Task Force 8: organization of preventive cardiology service. J Am Coll Cardiol. 1996;27: 1039-1047.
101. Grundy SM, Balady GJ, Criqui MH, et al. When to start cholesterol-lowering therapy in patients with coronary heart disease: a statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction. Circulation. 1997;95:1683-1685.